Chief Physician, born in September 1975, Head of Urology. He is a national committee member of the Chinese Medical Doctor Association's Urology Division, a national committee member of the Chinese Anti-Cancer Association's Urological and Male Reproductive System Tumors Division, and a standing committee member of the Prostate Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO). He also holds positions in various other national and provincial medical associations and is a co-founder of the Yangtze River Delta Urology Alliance.
Education and Work Experience
- September 1993 – June 1998: Bachelor’s in Clinical Medicine, Bengbu Medical College
- September 2004 – June 2007: Master’s in Urology, Anhui Medical University
- September 2008 – June 2011: Ph.D. in Urology, Sun Yat-sen University
- July 1998 – December 2003: Resident, Urology, Anhui Provincial Hospital
- January 2004 – November 2011: Attending Physician, Urology, Anhui Provincial Hospital
- December 2011 – November 2016: Associate Chief Physician, Urology, Anhui Provincial Hospital
- December 2016 – Present: Chief Physician, Urology, The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Academic Achievements and Impact
Dedicated to clinical practice, teaching, and research in urology for over 20 years, mentoring over ten master's and doctoral students and two postdoctoral fellows. Awarded the third prize in Anhui Province Science and Technology Awards.
Ongoing Projects (Principal Investigator Only)
1. Role and Molecular Mechanism of TET1/exosome-derived miR-22-3p/BTG1 Signaling Axis in Chemotherapy Resistance of Bladder Cancer — National Natural Science Foundation General Project, 5.5 million CNY, 2021-01 to 2024-12
2. Evolution of the Immune Microenvironment in Chemotherapy-Resistant Bladder Cancer Described by Single-Cell RNA Sequencing — Key Project of USTC New Medicine, 8 million CNY, 2021-01 to 2022-12
Main Research Directions (Enrollment Specialties) and Content
Biology
1. Mechanisms of Tumorigenesis / Tumor Immunity / Epigenetics
2. Screening and Detection of Early Tumor Markers
3. Mechanisms of Antitumor Drug Resistance
Clinical Medicine
Research on the occurrence and resistance mechanisms of urological tumors.
Representative Papers (Last Five Years)
1. Qingyu Ge, Meiduo Wang, Yao Lin, Congyun Xu, Jun Xiao*, Zhou Shen. Establishment of Animal Model Manifested as Bladder Neurogenic Changes Generated by Bilateral Pelvic Nerve Injury in Male Rats. *Int Urol Nephrol*, 2021, 53(3):421-429.
2. Fei Meng, Naitong Sun, Dongyan Liu, Jia Jia, Jun Xiao*, Haiming Dai. BCL2L13: Physiological and Pathological Meanings. *Cellular and Molecular Life Science*, 2021, 78(6):2419-2428.
3. Tao Tao, Deyun Shen, Lei Yuan, Ailiang Zeng, Kaiguo Xia, Bin Li, Qingyu Ge, Jun Xiao*. Establishing a Novel Prediction Model for Improving the Positive Rate of Prostate Biopsy. *Transl Androl Urol*, 2020, 9(2):574-582.
4. Jun Xiao, Sanqiang Niu, Jiahong Zhu, Lei Lv, Hui Deng, Daqing Pan, Deyun Shen, Congyun Xu, Zhou Shen, Tao Tao. miR‑22‑3p Enhances Multi‑Chemoresistance by Targeting NET1 in Bladder Cancer Cells. *Oncol Rep*, 2018, 39(6):2731-2740.
5. Tao T, Zhao F, Xuan Q, Shen Z, Xiao J*, Shen Q. Fenofibrate Inhibits the Growth of Prostate Cancer Through Regulating Autophagy and Endoplasmic Reticulum Stress. *Biochem Biophys Res Commun*, 2018, 503(4):2685-2689.
6. Tao T, Chen M, Jiang R, Guan H, Huang Y, Su H, Hu Q, Han X, Xiao J*. Involvement of EZH2 in Aerobic Glycolysis of Prostate Cancer Through miR-181b/HK2 Axis. *Oncol Rep*, 2017, 37(3):1430-1436.
7. Huang Y, Zou X, Zhang X, Wang F, Zhu W, Zhang G, Xiao J*, Chen M. Magnolin Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo. *Biomed Pharmacother*, 2017, 87:714-720.
Contact Information
E-mail: ixiaojun@ustc.edu.cn
Phone: 0551-62283522